Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63323-0373-02 63323-0373 ONDANSETRON HYDROCHLORIDE Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 In Use
63323-0374-20 63323-0374 ONDANSETRON HYDROCHLORIDE Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 In Use
63323-0376-01 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0376-04 63323-0376 OCTREOTIDE ACETATE Octreotide 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-01 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0377-04 63323-0377 OCTREOTIDE ACETATE Octreotide 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0378-05 63323-0378 OCTREOTIDE ACETATE Octreotide 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0379-05 63323-0379 OCTREOTIDE ACETATE Octreotide 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous March 14, 2006 In Use
63323-0450-50 63323-0450 PEMETREXED DISODIUM Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0506-01 63323-0506 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 29, 2003 In Use
63323-0506-16 63323-0506 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 29, 2003 In Use
63323-0516-10 63323-0516 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous April 5, 2005 In Use
63323-0572-70 63323-0572 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous May 10, 2017 In Use
63323-0621-00 63323-0621 PEMETREXED DISODIUM Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0622-00 63323-0622 PEMETREXED DISODIUM Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0631-10 63323-0631 Leucovorin Calcium Leucovorin Calcium 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Jan. 31, 2017 In Use
63323-0631-50 63323-0631 Leucovorin Calcium Leucovorin Calcium 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous July 27, 2018 In Use
63323-0637-10 63323-0637 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Aug. 31, 2018 In Use
63323-0650-10 63323-0650 Oxaliplatin Oxaliplatin Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 May 21, 2015 No Longer Used
63323-0650-17 63323-0650 Oxaliplatin Oxaliplatin Chemotherapy Alkylating Agent Platinum Compound Intravenous May 30, 2012 May 21, 2015 No Longer Used
63323-0650-20 63323-0650 Oxaliplatin Oxaliplatin Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 May 21, 2015 No Longer Used
63323-0650-27 63323-0650 Oxaliplatin Oxaliplatin Chemotherapy Alkylating Agent Platinum Compound Intravenous May 30, 2012 May 21, 2015 No Longer Used
63323-0673-05 63323-0673 Palonosetron Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
63323-0673-89 63323-0673 Palonosetron Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 In Use
63323-0710-50 63323-0710 Leucovorin Calcium Leucovorin Calcium 200.0 mg/20mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Sept. 18, 2010 In Use
63323-0710-59 63323-0710 Leucovorin Calcium Leucovorin Calcium 200.0 mg/20mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Sept. 18, 2010 In Use
63323-0711-00 63323-0711 Leucovorin Calcium Leucovorin Calcium 500.0 mg/50mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Sept. 18, 2010 In Use
63323-0715-05 63323-0715 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular May 20, 2019 In Use
63323-0733-10 63323-0733 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sept. 5, 2001 In Use
63323-0733-11 63323-0733 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sept. 5, 2001 In Use
63323-0734-10 63323-0734 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 19, 2002 Aug. 27, 2015 No Longer Used
63323-0735-10 63323-0735 Pamidronate Disodium Pamidronate Disodium 9.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 19, 2002 Aug. 27, 2015 In Use
63323-0750-10 63323-0750 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 In Use
63323-0750-17 63323-0750 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 Jan. 17, 2019 In Use
63323-0750-20 63323-0750 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 In Use
63323-0750-27 63323-0750 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 11, 2010 Jan. 17, 2019 In Use
63323-0760-20 63323-0760 Melphalan Hydrochloride Melphalan Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 22, 2017 In Use
63323-0762-10 63323-0762 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 30, 2010 In Use
63323-0762-17 63323-0762 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 30, 2010 Dec. 26, 2018 In Use
63323-0762-55 63323-0762 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 30, 2010 March 18, 2016 In Use
63323-0762-57 63323-0762 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 30, 2010 March 18, 2016 In Use
63323-0762-94 63323-0762 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 30, 2010 In Use
63323-0763-05 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 20, 2009 In Use
63323-0763-06 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 15, 2014 Jan. 31, 2017 In Use
63323-0763-16 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 20, 2009 In Use
63323-0763-17 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 15, 2014 Dec. 31, 2016 In Use
63323-0763-50 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 20, 2009 In Use
63323-0763-52 63323-0763 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 15, 2014 Feb. 28, 2017 In Use
63323-0771-39 63323-0771 Azacitidine Azacitidine 100.0 mg/30mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 16, 2017 In Use
63323-0772-30 63323-0772 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 4, 2011 In Use
63323-0821-10 63323-0821 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
63323-0825-20 63323-0825 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 2, 2019 In Use
63323-0883-05 63323-0883 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous April 14, 2000 In Use
63323-0883-10 63323-0883 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous April 14, 2000 In Use
63323-0883-30 63323-0883 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous April 14, 2000 In Use
63323-0926-88 63323-0926 Romidepsin Romidepsin Chemotherapy Enzyme Inhibitor HDAC Intravenous Oct. 12, 2021 In Use
63323-0961-98 63323-0961 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Sept. 4, 2014 In Use
63323-0972-10 63323-0972 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
63459-0103-10 63459-0103 Rituximab-abbs Truxima 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous May 4, 2020 In Use
63459-0104-50 63459-0104 Rituximab-abbs Truxima 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous May 4, 2020 In Use
63459-0177-14 63459-0177 Omacetaxine Mepesuccinate Synribo 3.5 mg/mL Chemotherapy Plant Alkaloid BCR-ABL Subcutaneous Nov. 19, 2012 April 30, 2024 In Use
63459-0303-43 63459-0303 TRASTUZUMAB HERZUMA 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous March 16, 2020 In Use
63459-0305-47 63459-0305 TRASTUZUMAB HERZUMA Immunotherapy Monoclonal Antibody HER2 March 16, 2020 In Use
63459-0348-04 63459-0348 Bendamustine Hydrochloride Bendeka 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 8, 2015 In Use
63459-0390-08 63459-0390 Bendamustine Hydrochloride Treanda 25.0 mg/5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 5, 2010 In Use
63459-0391-20 63459-0391 Bendamustine Hydrochloride Treanda 100.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous March 31, 2008 In Use
63459-0395-02 63459-0395 Bendamustine Hydrochloride Treanda 45.0 mg/.5mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 5, 2014 April 30, 2017 No Longer Used
63459-0396-02 63459-0396 Bendamustine Hydrochloride Treanda 180.0 mg/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 5, 2014 May 31, 2017 No Longer Used
63459-0600-10 63459-0600 Arsenic Trioxide Trisenox 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Oct. 15, 2000 Aug. 15, 2021 No Longer Used
63459-0601-06 63459-0601 Arsenic Trioxide Trisenox 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Dec. 22, 2017 In Use
63459-0910-01 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0910-11 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0910-12 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0910-15 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0910-17 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
63459-0910-18 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Jan. 7, 2015 In Use
63459-0910-36 63459-0910 tbo-filgrastim Granix 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
63459-0912-01 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-11 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-12 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-15 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 11, 2013 In Use
63459-0912-17 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
63459-0912-18 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Jan. 7, 2015 In Use
63459-0912-36 63459-0912 tbo-filgrastim Granix 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous March 2, 2015 In Use
63459-0918-59 63459-0918 tbo-filgrastim GRANIX 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 7, 2018 In Use
63459-0920-59 63459-0920 tbo-filgrastim GRANIX 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Nov. 7, 2018 In Use
63539-0026-01 63539-0026 Axitinib Inlyta 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 27, 2012 In Use
63539-0044-01 63539-0044 Axitinib Inlyta 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 27, 2012 In Use
63539-0044-02 63539-0044 Axitinib Inlyta 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan. 27, 2012 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
63539-0189-11 63539-0189 Palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Feb. 3, 2015 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 1, 2019 In Use
63539-0252-02 63539-0252 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug. 15, 2023 In Use
63539-0284-03 63539-0284 palbociclib Ibrance 75.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
63539-0295-30 63539-0295 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 10, 2018 In Use
63539-0486-03 63539-0486 palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
63539-0688-03 63539-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
63539-0927-01 63539-0927 Lorlatinib Lorbrena 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Oral Jan. 3, 2023 In Use
63561-0120-01 63561-0120 PredniSONE PredniSONE Tablets, USP, 5 mg 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 6, 2024 In Use

Found 10,000 results in 11 milliseconds — Export these results